- Tytuł:
-
A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with
Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics. - Autorzy:
- Źródło:
- Child psychiatry and human development [Child Psychiatry Hum Dev] 2023 Oct; Vol. 54 (5), pp. 1360-1372. Date of Electronic Publication: 2022 Mar 16.
- Typ publikacji:
- Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
- MeSH Terms:
-
Autism Spectrum Disorder */drug therapy
Autistic Disorder*/diagnosis
Humans ; Child ; Male ; Adolescent ; Female ; Bumetanide/adverse effects ; Double-Blind Method ; Treatment Outcome
Czasopismo naukowe